Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2009

View Archived Issues

Data from first-in-human study of PF-00547659 in ulcerative colitis patients presented

Clinical data on mesalamine formulations in Crohn's disease, ulcerative colitis presented

Novel viral fusion inhibitors for the treatment of HIV disclosed

Novartis claims S1P1 receptor agonists for the treatment of autoimmune conditions

Novel GPR38 receptor agonists claimed by GlaxoSmithKline for gastrointestinal disorders

Antisense reports results from mouse studies of ATL-1101 in prostate cancer

Snapshots: promising clinical data on novel treatments for genitourinary cancer presented at ASCO

CK-2017357 begins first-in-man study

Grant supports Pharming's study of human lactoferrin for IBD

FDA approves Allergan's Ozurdex for macular edema following retinal vein occlusion

Akorn acquires TB drug Capastat Sulfate from Lilly

Adimab launches human antibody discovery platform and enters into two collaborations

Penwest and Otsuka sign third research and development agreement for TimerX technology

Advinus files IND with DCGI for a type 2 diabetes drug

Enrollment completed in phase IIb Albuferon trial in chronic hepatitis C

Dainippon Sumitomo obtains additional indication approval for AmBisome

Beneficial effects on glycemic control seen with albiglutide in clinical studies

Novel PDE4 inhibitors claimed by deCODE Genetics for the treatment of stroke

Phase I data disclosed on XOMA-052, a new anti-inflammatory approach for type 2 diabetes therapy

FDA grants pediatric exclusivity for The Medicines Company's Angiomax

Linagliptin shows clinical glycemic control in type 2 diabetes and aids wound healing in ob/ob mice

Patrys reports preclinical safety data for PAT-LM1 and PAT-SM6

BioLineRx announces results from preclinical studies of BL-1020 for schizophrenia

Results from pivotal clinical trial of lestaurtinib in AML reported by Cephalon

BL-5010 scheduled to begin phase I/II clinical trial in nonsurgical removal of skin lesions